Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.33 |
| ▸ | ERN1 | O75460 | 5/20 | 0.32 |
| ▸ | PPARG | P37231 | 4/20 | 0.31 |
| ▸ | PPARD | Q03181 | 3/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040434 | 0.81 | FFAR1 (0.34) | PPARAPPARGFFAR1 | |
| SCHEMBL5043444 | 0.75 | EPHX2 (0.36) | PPARAERN1 | |
| SCHEMBL5043438 | 0.75 | EPHX2 (0.36) | PPARAERN1 | |
| Acetic Acid SCHEMBL5041496 | 0.74 | ST14 (0.41) | — | |
| SCHEMBL5037756 | 0.74 | PPARA (0.38) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL5037928 | 0.73 | FFAR1 (0.32) | PPARAPPARGFFAR1 | |
| SCHEMBL9945895 | 0.70 | TYR (0.39) | ERN1 | |
| SCHEMBL5037527 | 0.70 | CA12 (0.36) | PPARAPPARGFFAR1 | |
| SCHEMBL5041031 | 0.69 | CA12 (0.36) | — | |
| SCHEMBL5038048 | 0.68 | PTGS2 (0.39) | PPARAPPARGPPARDFFAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | PPARA 4124/4885ERN1 1226/4885PPARG 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.